Psychopharmacological treatment and quality of life in obsessive compulsive disorder

dc.contributor.authorBesiroglu, Luetfullah
dc.contributor.authorUguz, Faruk
dc.contributor.authorYilmaz, Ertan
dc.contributor.authorAgarun, Mehmet Yucel
dc.contributor.authorAskin, Ruestem
dc.contributor.authorAydin, Adem
dc.date.accessioned2020-03-26T17:27:33Z
dc.date.available2020-03-26T17:27:33Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: Obsessive compulsive disorder (OCD) is on illness that considerably influences the family, academic, occupational and social functioning of patients. In this study, we aimed to investigate the impact of psychopharmacological treatment on quality of life in patients with OCD. Method: Using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HDRS) and the World Health Organization Quality of Life Measurement Instrument Short Form, Turkish Version (WHOQOL-Bref TR) we assessed 53 patients who met the DSM-IV criteria for OCD to establish baseline values. The patients were consecutively assigned to receive either sertraline (100-200 mg/day), fluvoxamine (200-300 mg/day) or paroxetine (40-80 mg/day). We reassessed 36 (68%) of the initial group after 12 weeks. Results: The scores of obsession, compulsion and depression severity at follow-up were significantly lower than those of baseline scores. There is no significant difference between the pre and post-treatment quality of life domain scores. While psychological health scores at follow-up was significantly associated with baseline HDRS scores (r=-0.35, p<0.05), social relationship scores at follow-up was significantly associated with baseline social relationship scores (r=0.63, p<0.001) and compulsion scores (r=-0.37, p<0.05). Regression analyses revealed that social relationship scores at follow-up was associated with baseline compulsion severity whereas other follow-up quality of life domain scores were not predicted by any baseline variable. Conclusions: Clinical viewpoint and objective evaluations should be essential in the evaluation of treatment outcome, and quality of life researches may be important complement to clinical researches.en_US
dc.identifier.endpage45en_US
dc.identifier.issn1300-2163en_US
dc.identifier.issue1en_US
dc.identifier.pmid18330742en_US
dc.identifier.startpage38en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22591
dc.identifier.volume19en_US
dc.identifier.wosWOS:000254040300006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.publisherTURKIYE SINIR VE RUH SAGLIGI DERNEGIen_US
dc.relation.ispartofTURK PSIKIYATRI DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectobsessive compulsive disorderen_US
dc.subjectpsychophormacologyen_US
dc.subjectselective serotonin reuptake inhibitorsen_US
dc.subjectquality of lifeen_US
dc.subjectpsychological healthen_US
dc.subjecttreatmenten_US
dc.titlePsychopharmacological treatment and quality of life in obsessive compulsive disorderen_US
dc.typeArticleen_US

Dosyalar